-
Innovation Ranking
NewInnovation Ranking – Lee & Man Paper Manufacturing Ltd
Lee & Man Paper Manufacturing Ltd (Lee & Man) is an investment holding company. The company carries out the manufacturing and distribution of paper and packaging products. Its product portfolio includes the pulp kraft linerboards, test linerboards, coated duplex boards, and high strength corrugating medium. These products are used to produce corrugated boards and carton boxes. Lee & Man also operates recyclable corrugated containers collection. It operates plants in Guangdong, Jiangsu, Dongguan, Jiangxi, Jiangsu, Vietnam, and Chongqing across China. The...
-
Innovation Ranking
NewInnovation Ranking – Lee Enterprises Inc
Lee Enterprises Inc (Lee Enterprises) is a provider and publisher of news, information, advertising, and digital services. It offers retail, classified, national, digital, and niche publication advertisement services. The company uses print and digital platforms to market news, information, and advertisements. It provides online services like content management and web hosting. Lee Enterprises offers small and medium-sized businesses digital marketing services like local online marketing, search engine optimization, video advertising, website design, and social media marketing. The company offers its...
-
Sector Analysis
NewMalaysia Construction Market Size, Trend Analysis by Sector, Competitive Landscape and Forecast to 2028
Malaysia Construction Market Overview The Malaysia construction market size was $30.1 billion in 2023. The market will achieve an AAGR of more than 5% during 2025-2028, driven by investments in leisure and hospitality infrastructure, manufacturing facilities, roads, and renewable energy. Malaysia Construction Market Outlook, 2023-2028 ($ Billion) Buy the Full Report to Know More about the Malaysia Construction Market Forecast Download a Free Report Sample The Malaysia construction market research report gives a comprehensive understanding of project types and construction...
-
Thematic Analysis
NewGlobal Tech, Media, and Telecom (TMT) M&A Deals 2023 – Top Themes and Predictions – Thematic Intelligence
Global Tech, Media, and Telecom (TMT) M&A Deals 2023 Theme and Predictions Report Overview Total M&A deal value in the technology, media, and telecom (TMT) sector declined 46% in 2023, compared to the previous year. Software and services accounted for over 48% share of the total M&A deal value in 2023. The ‘Global Tech, Media, And Telecom (TMT) M&A Deals 2023 Theme and Predictions Report’ analyzes the top disruptive themes that drove M&A activity in the technology, media, and telecom (TMT)...
-
Product Insights
NewSpinal Fusion Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Spinal Fusion Pipeline Market Report Overview Spinal Fusion procedures are mainly performed on the cervical and thoracolumbar regions. Spinal fusion is a surgical procedure that involves joining two vertebrae in the spine to form a single solid bone, with the involvement of certain devices, to relieve pain. Conventional and Minimally Invasive Surgery (MIS) methods are used to perform Spinal Fusion. Conventional methods include all open surgical methods that are used for performing spinal procedures. The Spinal Fusion pipeline market research...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Non-Small Cell Lung Cancer Drug Details: Margetuximab (Margenza)...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Margetuximab in Extrahepatic Bile Duct Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Margetuximab in Extrahepatic Bile Duct Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Margetuximab in Extrahepatic Bile Duct Cancer Drug Details: Margetuximab (Margenza)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – BMS-986218 in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BMS-986218 in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BMS-986218 in Melanoma Drug Details: BMS-986218 is under development for the treatment of...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – GZR-18 in Type 2 Diabetes
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - GZR-18 in Type 2 Diabetes report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. GZR-18 in Type 2 Diabetes Drug Details: GZR-18 is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Divarasib in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Divarasib in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Divarasib in Non-Small Cell Lung Cancer Drug Details: Divarasib (GDC-6036...